Mukherjee will be succeeded by Erez Israeli, former president and CEO of Enzymotec. Israeli will join Dr. Reddy's on April 2, 2018, as chief operating officer and global head of generics and PSAI, based out of Hyderabad.
Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Ltd., where he held several positions of responsibility including vice president marketing and sales for North America, vice president Asia Operations, president Teva API, group executive vice president, head of global quality, and president and CEO growth markets.
Dr. Reddy's is committed to providing affordable and innovative medicines through its three businesses - pharmaceutical services and active ingredients, global generics, and proprietary products.
The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe, including the US, India, Russia and CIS countries, and Europe.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy